PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Immune checkpoint inhibitors may work in brain cancers

ESMO Symposium on Immuno-Oncology 2014

2014-11-21
(Press-News.org) Lugano/Geneva, Switzerland, 21 November 2014 - New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

The novel research shows that brain metastases have dense concentrations of tumour infiltrating lymphocytes, providing an immunoactive environment. Moreover, both primary and secondary brain cancers often exhibit high expression of the immunosuppressive factor programmed cell death ligand 1 (PDL1), which can be inhibited by new treatments, thus activating the immune system.

Berghoff, resident at the Department of Medicine I, Comprehensive Cancer Centre-CNS Tumours Unit, Medical University of Vienna, Austria, said: "Patients with glioblastoma and brain metastases have very few treatment options and usually die within a short period of time."

Immune checkpoint inhibitors are a new group of cancer treatments that work by boosting the patient's immune response to the tumour. The immune system operates differently in the brain in comparison to other organs. "Our study was designed to find out whether the immune system is activated and working in brain tumours, which would provide the foundation for immune checkpoint inhibitors to work," Berghoff explained.

The study included 117 patients with glioblastoma and 116 patients with brain metastases. Using immunohistochemistry the researchers looked for the presence of T-cells --also called tumour infiltrating lymphocytes-- in the tumours and whether they were accentuated in different areas of the tumour. T-cells are the main effector cells of the immune response and can be boosted by immune checkpoint inhibitors. They also looked for PDL1 --an immunosuppressive protein that influences responses to immune checkpoint inhibitors.

The researchers found that patients with glioblastoma had fewer T-cells, and therefore less activation of the immune system, than patients with brain metastases who had high concentrations of T-cells. They also found that PDL1 was common in both glioblastoma and brain metastases, with glioblastoma showing particularly high PDL1 positivity.

Berghoff said: "We saw that these brain tumour types have a different interaction with the immune system. The glioblastoma actively suppresses the immune system and there is little immune response. In contrast the brain metastases do a little less suppression of the immune system and there are a lot more tumour infiltrating lymphocytes."

Berghoff said the findings demonstrate that the immune system interacts with glioblastoma and brain metastases, which is evidence that immune checkpoint inhibitors may work: "We have arguments for conducting clinical studies with immune checkpoint inhibitors in patients with glioblastoma and brain metastases. In both tumour types we commonly see high expression of PDL1, an immunosuppressive factor which can be inhibited with new treatments. By inhibiting the suppression you can activate the immune system which in theory would work in brain cancers."

She continued: "We know that immune checkpoint inhibitors are more effective in immunoactive microenvironments. In brain metastases we see dense infiltration with T-cells which provides a good background for immune checkpoint inhibitors."

Small preliminary studies have shown efficacy of immune checkpoint inhibitors in melanoma brain metastases. However, melanoma is only the third most common brain metastases, the most common being non-small-cell lung cancer. Immune checkpoint inhibitors are active in extracranial metastasised lung cancer but it is unknown whether this holds true for patients with brain metastases. Data on immune checkpoint inhibitors in glioblastoma exists only in mice.

Berghoff said: "Our study shows that T-cells and PDL1 expression are present in glioblastoma and brain metastases. This means that the targets for novel drugs that activate the immune system against cancer cells are present and brain tumours may be effectively treatable with such drugs."

She concluded: "Our data strongly support the launch of clinical trials with immune checkpoint inhibitors, especially the ones targeting the PD1/PDL1 axis, in patients with glioblastoma and brain metastases. Indeed, some early studies are being designed and started at the moment. In addition, profiling of other immune checkpoint molecules and modes of immune escape in brain tumours need to be identified to prepare for the development of next generation immunomodulators."

Commenting on the implications of the findings for patients with glioblastoma and brain metastases, Professor Martin J. van den Bent, of the Neuro-Oncology Unit, Erasmus Medical Centre, Rotterdam, the Netherlands, said: "The investigators found different immune reactions to the malignant process in the brain that were related to the type of cancer. It is quite interesting that the immune system does play a role in brain metastases as well. The findings indicate that therapeutic interventions for brain cancers that use the immune system should be explored."

Van den Bent noted that brain metastases are not a homogenous group but vary depending on the primary tumour. He said: "I would guess that the type of immune reaction to brain metastases will differ between the various tumour types. We know that the mechanism with which metastases arise can be completely different between the various diseases."

"The debate on the penetration through the intact blood brain barrier and how significant that is for treatment effectiveness is still on the table," continued van den Bent. "But the general understanding is that any therapy that works for a specific type of cancer will also work if it has metastasised to the brain provided the access is good."

INFORMATION:

Notes 1O - Role of PDL1 expression and tumour infiltrating lymphocytes (TILs) in glioblastoma (GBM) and brain metastases (BM)"

Session 1O - Friday, November 21 2014 - Session 6 - 17:25 CET.

Disclaimer Information contained in this press release was provided by the abstracts authors and reflects the content of the studies. It does not necessarily express ESMO's point of view.

About the European Society for Medical Oncology The European Society for Medical Oncology (ESMO) is the leading European professional organization committed to advancing the specialty of medical oncology and promoting a multidisciplinary approach to cancer treatment and care. ESMO's mission is to advance cancer care and cure through fostering and disseminating good science that leads to better medicine and determines best practice. ESMO's scientific journal, Annals of Oncology, ranks among the top clinical oncology journals worldwide. ESMO events are the meeting place in Europe for medical oncologists to update their knowledge, to network and to exchange ideas. To find out more about ESMO, please visit: http://www.esmo.org

Abstract: 1O 1O - ROLE OF PDL1 EXPRESSION AND TUMOR INFILTRATING LYMPHOCYTES (TILS) IN GLIOBLASTOMA (GBM) AND BRAIN METASTASES (BM)

A.S. Berghoff1, A.W. Wöhrer2, G. Widhalm3, F. Oberndorfer4, K. Dieckmann5, M. Filipits1, C. Marosi1, C. Höller6, W. Wick7, M. Preusser1 1Department of Medicine I, Medical University of Vienna, Vienna, AUSTRIA, 2Institute of Neurology, Medical University of Vienna, Vienna, AUSTRIA, 3Department of Neurosurgery, Medical University of Vienna, Vienna, AUSTRIA, 4Clinical Institute of Pathology, Medical University of Vienna, Vienna AUSTRIA, 5Department of Radiotherapy, Medical University of Vienna, Vienna, AUSTRIA, 6Department of Dermatology, Medical University of Vienna, Vienna, AUSTRIA, 7Neurology Clinic and National Center for Tumor Disease, University of Heidelberg, Heidelberg, GERMANY

Background: Differences in the adaptive immune response to various kinds of brain tumors have been poorly characterized.

Methods: We immunostained 287 neurosurgical specimens: 170 BM (lung cancer: 77 (45.3%); breast cancer: 17 (10.0%); melanoma 44 (25.9%); renal cell carcinoma 10 (5.9%) others 22 (7.7%)) and 117 GBM for CD3 (n=287), CD8 (n=287), PD1 (n=287) and PDL1 (n=234) and used previously published semiquantitative evaluation criteria.

Results: TIL infiltration of variable density (sparse to dense) was found in 161/170 (94.7%) BM and 78/117 (66.6%) GBM. TILs were predominantly present in the tumor stroma and perivascular areas in BM and in perivascular area in GBM. Dense infiltration with CD3+ TILs (p END



ELSE PRESS RELEASES FROM THIS DATE:

Life's extremists may be an untapped source of antibacterial drugs

Lifes extremists may be an untapped source of antibacterial drugs
2014-11-21
One of the most mysterious forms of life may turn out to be a rich and untapped source of antibacterial drugs. The mysterious life form is Archaea, a family of single-celled organisms that thrive in environments like boiling hydrothermal pools and smoking deep sea vents which are too extreme for most other species to survive. "It is the first discovery of a functional antibacterial gene in Archaea," said Seth Bordenstein, the associate professor of biological sciences at Vanderbilt University who directed the study, "You can't overstate the significance of the antibiotic ...

Research examines an emerging issue: Treatment of transgendered prison populations

Research examines an emerging issue: Treatment of transgendered prison populations
2014-11-21
Prison policies vary on treating transgendered inmates, which could put inmates and institutions at risk. Gina Gibbs, a University of Cincinnati criminal justice doctoral student, will present a synopsis of the legal issues posed by such inmates at the annual meeting of the American Society of Criminology. The national conference runs from Nov. 19-22 in San Francisco. At the center of the debate are Eighth Amendment protections against cruel and unusual punishment, widely varying policies on the treatment of transgendered populations and, Gibbs says, court crackdowns ...

Not all baseball stars treated equally in TV steroid coverage, says study of network news

Not all baseball stars treated equally in TV steroid coverage, says study of network news
2014-11-21
CHAMPAIGN, Ill. -- Retired baseball stars Barry Bonds, Mark McGwire and Rafael Palmeiro each had Hall of Fame-worthy numbers, each hitting more than 500 home runs. All three also were tarred by allegations of steroid use. Their stories, however, received very different treatment over 12 years of national television news coverage, says University of Illinois professor Brian Quick, lead author on a paper about that coverage and its effects, published online Nov. 20 by the journal Communication Research. "We found that Bonds received more than twice as many negative stories ...

When shareholders exacerbate their own banks' crisis

2014-11-21
This news release is available in German. One lesson that policymakers and financial regulators have drawn from the financial market crisis is that banks need to be backed by more equity. But banks have found it hard to increase their core capital positions - in other words, the equity available to them long-term. Since 2009, this has led European banks to increasingly deploy an instrument that allows them to convert debt into equity in times of need: contingent convertible bonds, also known as CoCo bonds. Banks issue these bonds at fixed interest rates - as is normal ...

A coating that protects against heat and oxidation

A coating that protects against heat and oxidation
2014-11-21
Gases don't conduct heat as well as solids do. Cellular or aerated concretes take advantage of this effect, which experts call "gas-phase insulation". The heat barrier is achieved by air encased in the cavities of the concrete. But gas-phase insulation has far greater potential than keeping our homes warm. It can also be used to protect turbine engine and waste incinerator components when subjected to intense heat. All you need to do is transfer this effect to a coating that is just a few hundred micrometers thick. Temperature differences of over 400 degrees Celsius Scientists ...

Type 2 diabetes: Added benefit of canagliflozin plus metformin is not proven

2014-11-21
The fixed combination of canagliflozin with metformin (trade name: Vokanamet) has been approved since April 2014 for adults with type 2 diabetes mellitus in whom diet and exercise do not provide adequate glycaemic control. The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in a dossier assessment whether the new drug combination offers an added benefit over the appropriate comparator therapy. No such added benefit can be derived from the dossier, however, because the manufacturer did not present any suitable data for any of the possible ...

Possibilities for personalized vaccines revealed at ESMO symposium

2014-11-21
Lugano/Geneva, Switzerland, 21 November 2014 - The possibilities for personalised vaccines in all types of cancer are revealed today in a lecture from Dr Harpreet Singh at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland. "One of the biggest hurdles in cancer immunotherapy is the discovery of appropriate cancer targets that can be recognised by T-cells," said Singh, who is scientific coordinator of the EU-funded GAPVAC phase I trial which is testing personalised vaccines in glioblastoma, the most common and aggressive brain cancer. "In the GAPVAC trial ...

New model of follow up for breast cancer patients

2014-11-21
Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health system perspective. International guidelines recommend annual follow-up mammograms for every woman after treatment for early breast cancer, regardless of the risk of her cancer returning. There is also no strong evidence to support annual mammography compared with other possible mammography schedules. In a paper published in the journal Value ...

Researchers study impact of power prosthetic failures on amputees

Researchers study impact of power prosthetic failures on amputees
2014-11-21
VIDEO: Powered lower limb prosthetics hold promise for improving the mobility of amputees, but errors in the technology may also cause some users to stumble or fall. New research from the... Click here for more information. Powered lower limb prosthetics hold promise for improving the mobility of amputees, but errors in the technology may also cause some users to stumble or fall. New research examines exactly what happens when these technologies fail, with the goal of developing ...

Update on new treatments for liver diseases

2014-11-21
Bethesda, MD (Nov. 21, 2014) -- Cirrhosis and nonalcoholic fatty liver disease (NAFLD) are two serious liver conditions with limited pharmacological treatments. The December issues of AGA's journals -- Clinical Gastroenterology and Hepatology and Gastroenterology -- highlight important updates into treatments for these two debilitating diseases. For access to any of these studies, or to speak with the study authors, please contact media@gastro.org or call 301-272-1603. Promising Probiotic for Liver Disease A study published in Gastroenterology1 found that, over a ...

LAST 30 PRESS RELEASES:

Doctors received approximately $12.1 billion from drug and device makers between 2013-2022

Discovery suggests new strategy against follicular lymphoma

Making the future too bright: how wishful thinking can point us in the wrong direction

Ochsner Health named to Newsweek’s America’s Greatest Workplaces 2024 for Job Starters

Three-year study of young stars with NASA’s Hubble enters new chapter

North Carolina takes the lead in PFAs research with Collaboratory’s $3 million investment to expand the state’s research capacity

Is it the school, or the students?

Exploring the relationship between HIV pre-exposure prophylaxis and the incidence of chlamydia, gonorrhea and syphilis – findings from Denmark

Music: Song lyrics have become simpler and more repetitive since 1980

Environment: More than half of Colorado River’s water used to irrigate crops

When inequality is more than “skin-deep”: Social status leaves traces in the epigenome of spotted hyenas in Tanzania

Study explores the future of at-home cancer treatment

First performance standards published to measure the effectiveness of lifestyle medicine treatments

To keep volunteers, connect them

Suppressing boredom at work hurts future productivity, study shows

Older brain cells linger unexpectedly before their death

Clear shift in arterial diseases in diabetes

Celebrating half a century of pioneering excellence: EBMT marks its 50th anniversary

Ancient DNA reveals the appearance of a 6th century Chinese emperor

DNA study IDs descendants of George Washington from unmarked remains, findings to aid service member IDs going back to World War II

Familial Alzheimer’s disease transferred via bone marrow transplant in mice

Perspectives of oncologists on the ethical implications of using AI for cancer care

Industry payments to US physicians by specialty and product type

Andrew E. Place, MD, PhD appointed as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Vice President, Pediatric Chief Medical Officer

COVID-19 antibody discovery could explain long COVID

Wild plants face viral surprise

Storing electrons from hydrogen for clean chemical reactions

Unlocking how to use mRNA to target Alzheimer’s disease

Kessler Foundation secures $770,000 in grants to advance leading-edge spinal cord research

Going ‘back to the future’ to forecast the fate of a dead Florida coral reef

[Press-News.org] Immune checkpoint inhibitors may work in brain cancers
ESMO Symposium on Immuno-Oncology 2014